Hepatocellular Carcinoma
Conditions
Keywords
Anlotinib, AL3818
Brief summary
To assess the primary effects and safety of Anlotinib with placebo in patients with Hepatocellular Carcinoma(HCC).
Interventions
DRUGAnlotinib
Anlotinib p.o. qd
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Conform to the clinical diagnosis standard strictly or histological or cytological confirmation of hepatocellular carcinoma who cannot benefit from treatments of ablative therapy * Liver function status Child-Pugh Class A or B (score≤8) * Enroll 2 group patients：Group A：No history of systematic chemotherapy/target therapy.Group B:Failed with Sorafenib(Last Sorafenib Therapy≥4 weeks ) * Last Therapy≥4 weeks (such as surgery, PCI,ablation, radiotherapy)，and the wound healing.Patients with adjuvant chemotherapy, last chemotherapy ≥6m * At least one measurable lesion (by RECIST1.1) * 18-75 years,ECOG PS:0-1,Life expectancy of more than 3 months * Main organs function is normal * Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped * Patients should participate in the study voluntarily and sign informed consent
Exclusion criteria
* Diagnosed with cholangiocellular carcinoma, mixed cell carcinoma and fibrolamellar hepatocellular carcinoma * History of other malignancy (except for non-melanoma skin cancer, cervix in situ carcinoma) * Liver function status Child-Pugh Class C (score\>9),with malignant ascites * HBV-DNA\>2000IU/mL * History of liver transplantation or prepare for it * Patients with any severe and/or unable to control diseases，including： 1. Blood pressure unable to be controlled ideally(systolic pressure≥150 mmHg，diastolic pressure≥100 mmHg); 2. Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QT≥480ms) and patients with Grade 1 or higher congestive heart failure (NYHA Classification); 3. Patients with active or unable to control serious infections; 4. Patients with poorly controlled diabetes (fasting blood glucose(FBG)\>10mmol/L) 5. Urine protein ≥ ++，and 24-hour urinary protein excretion\>1.0 g confirmed * Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism * Patients with drug abuse history and unable to get rid of or Patients with mental disorders * Imaging showed tumors have involved important blood vessels or by investigators determine likely during the follow-up study and cause fatal hemorrhage * Patients participated in other anticancer drug clinical trials within 4 weeks * History of immunodeficiency * Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 12-week Progression-free survival rate(PFR 12w) | From randomization，each 42 days up to PD or death(up to 24 months) |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR) | each 42 days up to intolerance the toxicity or PD (up to 24 months) |
| Disease Control Rate (DCR) | each 42 days up to intolerance the toxicity or PD (up to 24 months) |
| Overall Survival (OS) | From randomization until death (up to 24 months) |
| Serum Alpha-Fetoprotein level (AFP) | From randomization up to 24 months |
| Time to Progression(TTP) | From randomization，each 42 days up to PD or death(up to 24 months) |
| 24-week Progression-free survival rate(PFR 24w) | From randomization，each 42 days up to PD or death(up to 24 months) |
Countries
China
Contacts
Primary ContactAiping Zhou, doctor
Outcome results
None listed